Linzagolix information

Linzagolix
Clinical data
Pronunciation	/ˌlɪnzəˈɡoʊlɪks/; LINZ-ə-GOH-liks
Trade names	Yselty
Other names	KLH-2109; OBE-2109
Routes of; administration	By mouth
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
ATC code	H01CC04 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); EU: Rx-only;
Identifiers
	IUPAC name 3-{5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl}-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid;
CAS Number	935283-04-8; as choline: 1321816-57-2;
PubChem CID	16656889;
ChemSpider	17590169;
UNII	7CDW97HUEX;
KEGG	D11608; as choline: D11609;
ChEMBL	ChEMBL3668014; as choline: ChEMBL4298171;
Chemical and physical data
Formula	C22H15F3N2O7S
Molar mass	508.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F;
	InChI InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30); Key:BMAAMIIYNNPHAB-UHFFFAOYSA-N;

Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids.^[1]^[5] Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) developed by Kissei Pharmaceutical and ObsEva.^[6]^[7]^[2]

In June 2022, it was approved for medical use in the European Union and in the United Kingdom.^[1]^[4]^[8]

^ ^a ^b ^c ^d "Yselty EPAR". European Medicines Agency (EMA). 14 December 2021. Retrieved 19 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ^a ^b Ezzati M, Carr BR (January 2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
^ "Linzagolix". Specialist Pharmacy Service. 8 August 2022. Retrieved 24 August 2022.
^ ^a ^b "Yselty Product information". European Commission. EU/1/21/1606. Retrieved 24 June 2022.
^ "Yselty film-coated tablets" (PDF). Theramex Ireland Limited. European Medicines Agency.
^ "Linzagolix - Kissei Pharmaceutical/ObsEva". AdisInsight. Springer Nature Switzerland AG.
^ Chodankar R, Allison J (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.
^ Cite error: The named reference ObsEva2022 was invoked but never defined (see the help page).

[Yselty_EPAR-1] "Yselty EPAR". European Medicines Agency (EMA). 14 December 2021. Retrieved 19 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[pmid25581052-2] Ezzati M, Carr BR (January 2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.

[3] "Linzagolix". Specialist Pharmacy Service. 8 August 2022. Retrieved 24 August 2022.

[EU-approval-4] "Yselty Product information". European Commission. EU/1/21/1606. Retrieved 24 June 2022.

[Yselty-Label-5] "Yselty film-coated tablets" (PDF). Theramex Ireland Limited. European Medicines Agency.

[AdisInsight-6] "Linzagolix - Kissei Pharmaceutical/ObsEva". AdisInsight. Springer Nature Switzerland AG.

[ChodankarAllison2018-7] Chodankar R, Allison J (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.

[ObsEva2022-8] Cite error: The named reference ObsEva2022 was invoked but never defined (see the help page).

Linzagolix information

and 24 Related for: Linzagolix information

Linzagolix

Luteinizing hormone

Menotropin

Antigonadotropin

Gonadotropin preparations

Human chorionic gonadotropin

Puberty blocker

Gonadotropin

Triptorelin

Kissei

Feminizing hormone therapy

Goserelin

Transgender hormone therapy

Gonadorelin

Degarelix

Buserelin

Androgen deprivation therapy

Ganirelix

Megestrol acetate

Histrelin

Leuprorelin

List of antiandrogens

ATC code H01

Abarelix

Clinical data


Pronunciation	/ˌlɪnzəˈɡoʊlɪks/ LINZ-ə-GOH-liks
Trade names	Yselty
Other names	KLH-2109; OBE-2109
Routes of administration	By mouth^[1]^[2]
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
ATC code	H01CC04 (WHO)
Legal status
Legal status	UK: POM (Prescription only)^[3] EU: Rx-only^[1]^[4]
Identifiers
IUPAC name 3-{5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl}-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid
CAS Number	935283-04-8 as choline: 1321816-57-2
PubChem CID	16656889
ChemSpider	17590169
UNII	7CDW97HUEX
KEGG	D11608 as choline: D11609
ChEMBL	ChEMBL3668014 as choline: ChEMBL4298171
Chemical and physical data
Formula	C₂₂H₁₅F₃N₂O₇S
Molar mass	508.42 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F
InChI InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30) Key:BMAAMIIYNNPHAB-UHFFFAOYSA-N